Skip to main content

Advertisement

Log in

Biologic Therapy in the Treatment of Sjögren’s Syndrome: a Clinical Perspective

  • Other CTD: Inflammatory Myopathies and Sjogren's (P Basharat, Section Editor)
  • Published:
Current Treatment Options in Rheumatology Aims and scope Submit manuscript

Abstract

Purpose of review

Sjögren’s syndrome (SS) is an autoimmune disease characterized by sicca symptoms, musculoskeletal pain, and systemic manifestations. Biologic therapies have been successful in the treatment of autoimmune diseases and are being studied and used more extensively in SS. In this review, we discuss the burden of illness, challenges with clinical trials, new clinical practice guidelines, biologic therapies, and novel therapies in the treatment of SS.

Recent findings

Trials have shown that tumor necrosis factor-alpha (TNF-α) inhibitors are not helpful for most SS patients. Rituximab has demonstrated improvement in fatigue, gland function, and disease activity in small studies of SS though larger randomized-controlled-trials have failed to reach their primary endpoints. Non-controlled studies of belimumab and abatacept have reported positive results. New clinical practice guidelines have been published to assist in the management of SS including specific recommendations regarding the use of biologic therapies.

Summary

Biologic therapies show a lot of promise in the treatment of SS. Further studies are pending and new results will likely lead to future changes in the standard of care of this complex disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Vivino F. Sjögren’s syndrome: clinical aspects. Clin Immunol. 2017;182:48–54.

  2. Voulgarelis M, Dafni U, Isenberg D, et al. Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s Syndrome. Arthritis Rheum. 1999;42(8):1765–72. https://doi.org/10.1002/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V.

    Article  CAS  PubMed  Google Scholar 

  3. Baimpa E, Dahabreh I, Voulgarelis M, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88(5):284–93. https://doi.org/10.1097/MD.0b013e3181b76ab5.

    Article  Google Scholar 

  4. Smedby K, Vajdic C, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the Interlymph Consortium. Blood. 2008;111(8):4029–38. https://doi.org/10.1182/blood-2007-10-119974.

    Article  CAS  Google Scholar 

  5. Heaton JM. Sjögren’s syndrome and systemic lupus erythematosus. Br Med J. 1959;1(5120):466–9. https://doi.org/10.1136/bmj.1.5120.466.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Buchholz P, Steeds C, Stern L, et al. Utility assessment measure the impact of dry eye disease. Ocul Surf. 2006;4(3):155–61. https://doi.org/10.1016/S1542-0124(12)70043-5.

    Article  PubMed  Google Scholar 

  7. Fox R. Extraglandular manifestations of Sjögren syndrome (SS): dermatologic, arthritis, endocrine, pulmonary, cardiovascular, gastroenterology, renal, urology, and gynecologic manifestations. In: Fox R, Fox C, editors. Sjögren syndrome: practical guidelines to diagnosis and therapy. New York City: Springer; 2011.

    Google Scholar 

  8. Schiffman R, Walt J, Jacobsen G, et al. Utility assessment amongpatients with dry eyes disease. Ophthalmology. 2003;110(7):1412–9. https://doi.org/10.1016/S0161-6420(03)00462-7.

    Article  PubMed  Google Scholar 

  9. Christensen L, Petersen P, Thorn J, et al. Dental caries and dental health behavior of patients with primary Sjögren’s syndrome. Acta Odontol Scandinavica. 2001;59(3):116–2.

    Article  CAS  Google Scholar 

  10. Fox PC, Bowman SJ, Segal B, Vivino FB, Murukutla N, Choueiri K, et al. Oral involvement in primary Sjögren syndrome. J Am Dent Assoc. 2008;139(12):1592–601. https://doi.org/10.14219/jada.archive.2008.0101.

    Article  PubMed  Google Scholar 

  11. Sutcliffe N, Stoll T, Pyke S, Isenberg DA. Functional disability and end-organ damage in patients with systemic lupus and Sjögren’s syndrome. J Rheumatol. 1998;25(1):63–8.

    CAS  PubMed  Google Scholar 

  12. Valtysdottir ST, Gudbjornsson B, Hallgren R. Psychological well-being in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2000;18:597–600.

    CAS  PubMed  Google Scholar 

  13. Strombeck B, Ekdahl C, Manthorpe R, et al. Health related quality of life in primary Sjögren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol. 2000;29:20–8.

    Article  CAS  PubMed  Google Scholar 

  14. Zhang Q, Wang X, Chen H, Shen B. Sjögren’s syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence from Short Form 36 questionnaire and a meta-analysis. Patient Prefer Adherence. 2017;11:905–11. https://doi.org/10.2147/PPA.S132751.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Segal B, Bowman SJ, Fox PC, et al. Primary Sjögren’s syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009;7(46):1–9.

    Google Scholar 

  16. Stewart C, Berg K, Cha S, et al. Salivary dysfunction and quality of life in Sjögren syndrome: a critical oral-systemic connection. J Am Dent Assoc. 2008;139(3):291–9. https://doi.org/10.14219/jada.archive.2008.0158.

    Article  PubMed  Google Scholar 

  17. Callaghan R, Prabu A, Allan R, et al. UK Sjögren’s interest group, direct healthcare costs and predictors of costs in patients with primary Sjögren’s syndrome. Rheumatology. 2007;46(1):105–11. https://doi.org/10.1093/rheumatology/kel155.

    Article  CAS  PubMed  Google Scholar 

  18. Vitali C, Tavoni A, Neri R, et al. Fibromyalgia features in patients with primary Sjögren’s syndrome: evidence of a relationship with psychological depression. Scand J Rheumatology. 1989;18(1):21–7.

    Article  CAS  Google Scholar 

  19. Valtysdottir S, Gudbjornsson B, Lindqvist U, et al. Anxiety and depression in patients with primary Sjögren’s syndrome. J Rheumatol. 2000;27(1):165–9.

    CAS  PubMed  Google Scholar 

  20. Choi B, Oh H, Lee Y, et al. Prevalence in clinical impact of fibromyalgia in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2016;34(2 Suppl 96):S9–13.

    PubMed  Google Scholar 

  21. Ostuni P, Botsios C, Sfriso P, Punzi L, Chieco-Bianchi F, Semerano L, et al. Fibromyalgia in Italian patients with primary Sjögren’s. Joint Bone Spine. 2002;69(1):51–7. https://doi.org/10.1016/S1297-319X(01)00341-4.

    Article  PubMed  Google Scholar 

  22. Fox RI, Fox CM. Sjögren syndrome: why do clinical trials fail? Rheum Dis Clin N Am. 2016;42(3):519–30. https://doi.org/10.1016/j.rdc.2016.03.009.

    Article  Google Scholar 

  23. Jonsson R, Theander E, Sjöström B, Brokstad K, Henriksson G. Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA. 2013 Nov 6;310(17):1854–5. https://doi.org/10.1001/jama.2013.278448.

    Article  CAS  PubMed  Google Scholar 

  24. Trocchio E. The time is now for Sjögren’s. Moisture Seekers. 2016;34(1):12.

    Google Scholar 

  25. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjögren’s Task Force, EULAR Sjögren’s Syndrome Disease Activity Index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis. 2010;69(6):1103–9. https://doi.org/10.1136/ard.2009.110619.

    Article  PubMed  Google Scholar 

  26. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, et al. EULAR Sjögren’s Task Force. Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. 2015;74(5):859–66. https://doi.org/10.1136/annrheumdis-2013-204615.

    Article  PubMed  Google Scholar 

  27. Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, et al. Development of the Sjögren’s Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology (Oxford). 2015;54(9):1699–708. https://doi.org/10.1093/rheumatology/kev114.

    Article  CAS  Google Scholar 

  28. Taylor S, Trocchio E. SSF's national patient survey reveals significant physical and emotional burdens of Sjögren's. The Moisture Seekers. 2017;35(4):1–2, 4–7.

  29. Sullivan B, Crews L, Messmer E, et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol. 2014;92:161–6.

    Article  PubMed  Google Scholar 

  30. Shiboski S, Shiboski C, Criswell L, et al. Sjögren’s International Collaborative Clinical Alliance (SICCA) Research. American College of Rheumatology Classification Criteria for Sjögren’s Syndrome: a data driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance Cohort. Arthritis Care Res. 2012;64(4):475–87.

    Article  CAS  Google Scholar 

  31. Mishra R, Vivino F. Diagnosis and management of fatigue in Sjögren’s syndrome. In: Wallace D, Alexander E, Carsons S, Hammitt K, Vivino F, editors. The Sjögren’s book. 4th ed. New York: Oxford University Press; 2012.

    Google Scholar 

  32. Usmani Z, Hlavac M, Rischmueller M, et al. Sleep disordered breathing in patients with primary Sjögren’s syndrome: a group controlled study. Sleep Med. 2012;13(8):1066–70. https://doi.org/10.1016/j.sleep.2012.06.010.

    Article  PubMed  Google Scholar 

  33. Gudbjornsson B, Broman JE, Hetta J, et al. Sleep disturbances in patients with primary Sjögren’s syndrome. Br J Rheumatol. 1993;32(12):1072–6. https://doi.org/10.1093/rheumatology/32.12.1072.

    Article  CAS  PubMed  Google Scholar 

  34. Garcia-Carrasco M, Jiménez-Herrera E, Gálvez-Romero J, et al. Vitamin D and Sjögren syndrome. Autoimmun Rev. 2017;16(6):587–93. https://doi.org/10.1016/j.autrev.2017.04.004.

    Article  CAS  PubMed  Google Scholar 

  35. •• Vivino FB, Carsons SE, Foulks G, et al. New treatment guidelines for Sjögren’s disease. Rheum Dis Clin Am. 2016;42:531–51. Review of new guidelines for Sjögren’s syndrome including treatment of dry-mouth, dry-eye, musculoskeletal pain, fatigue and use of biologics.

    Article  Google Scholar 

  36. Foulks G, Forstot S, Donshik P, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. The ocular surface. 2015;13(2):118–32.

    Article  PubMed  Google Scholar 

  37. Zero D, Brennan M, Daniels T, et al. Clinical practice guidelines for oral management of Sjögren’s disease: dental caries prevention. J Am Dent Assoc. 2016;147(4):295–305.

    Article  PubMed  Google Scholar 

  38. •• Carsons S, Vivino F, Parke A, et al. Treatment guidelines for rheumatologic manifestations of Sjögren’s: use of biologics, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res. 2017;69(4):517–27. Review of new guidelines for Sjögren’s syndrome including treatment of musculoskeletal pain, fatigue, and use of biologics.

    Article  Google Scholar 

  39. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003;12(1):18–23.

    Article  Google Scholar 

  40. AGREE Research trust. Appraisal of Guidelines for Research and Evaluation II 2013. Available at http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users- Manual-and-23-item-Instrument_2009_UPDATE_2013.pdf.

  41. Guyatt G, Oxman A, Visit G, et al. For the GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–66. https://doi.org/10.1136/bmj.39489.470347.AD.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Zandbelt MM, de Wilde PCM, van Damme PA, et al. Etanercept in the treatment of patients with primary Sjögren’s syndrome: a pilot study. J Rheumatol. 2004;31(1):96–101.

    CAS  PubMed  Google Scholar 

  43. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren’s syndrome. Arthritis Rheum. 2004;50(4):1270–6. https://doi.org/10.1002/art.20146.

    Article  CAS  PubMed  Google Scholar 

  44. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebocontrolled pilot clinical trial. Arthritis Rheum. 2004;50(7):2240–45.

  45. Türkoğlu EB, Tuna S, Alan S, et al. Effect of systemic infliximab therapy in patients with Sjögren’s syndrome. Turkish J Ophthal. 2015;45(4):138–40.

    Google Scholar 

  46. Moutsopoulos NM, Katsifis GE, Angelov N, Leakan RA, Sankar V, Pillemer S, et al. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis. 2008;67(10):1437–43. https://doi.org/10.1136/ard.2007.077891.

    Article  CAS  PubMed  Google Scholar 

  47. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjögren’s syndrome treated with etanercept. Arthritis Rheum. 2007;56(12):3995–04. https://doi.org/10.1002/art.23062.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Kroese FG, Adbulahad WH, Haacke E, et al. B-cell hyperactivity in primary Sjögren’s syndrome. Expert Rev Clin Immunol. 2014;10(4):483–99. https://doi.org/10.1586/1744666X.2014.891439.

    Article  CAS  PubMed  Google Scholar 

  49. Pontarini E, Fabris M, Quartuccio L, Cappeletti M, Calcaterra F, Roberto A, et al. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjögren’s syndrome. Rheumatology. 2015;54(8):1429–34. https://doi.org/10.1093/rheumatology/kev005.

    Article  CAS  PubMed  Google Scholar 

  50. Brown S, Coy NN, Pitzalis C, et al. The TRACTISS protocol: a randomized double blind placebo controlled TRial of Anti-B Cell Therapy In patients with primary Sjögren's Syndrome. BMC Musculoskelet Disord. 2014:15–21. https://doi.org/10.1186/1471-2474-15-21

  51. Bowman SJ, Everett CC, O’Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis Rheumatol. 2017;69(7):1440–50. https://doi.org/10.1002/art.40093.

    Article  CAS  PubMed  Google Scholar 

  52. Devauchelle-Pensec V, Mariette X, Jousee-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233–42. https://doi.org/10.7326/M13-1085.

    Article  PubMed  Google Scholar 

  53. Meijer JM, Meiners PM, Vissink A, Spijkervet FKL, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome. Arthritis Rheum. 2010;62(4):960–8. https://doi.org/10.1002/art.27314.

    Article  CAS  PubMed  Google Scholar 

  54. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541–4. https://doi.org/10.1136/ard.2007.083865.

    Article  CAS  PubMed  Google Scholar 

  55. Gottenberg J, Ciquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026–31. https://doi.org/10.1136/annrheumdis-2012-202293.

    Article  CAS  PubMed  Google Scholar 

  56. Mekinian A, Pavaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous systemic involvement: results from the AIR registry. Ann Rheum Dis. 2012;71:84–7.

    Article  CAS  PubMed  Google Scholar 

  57. Bootsma H, Kroese FGM, Vissink A. Editorial: rituximab in the treatment of Sjögren's syndrome: is it the right or wrong drug? Arthritis rheumatol. 2017;69(7):1346–49.

  58. Steinfeld SD, Tant L, Burmester GR, Teoh NKW, Wegener WA, Goldenberg DM, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8(4):R129. https://doi.org/10.1186/ar2018.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526–31. https://doi.org/10.1136/annrheumdis-2013-203991.

    Article  CAS  PubMed  Google Scholar 

  60. De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology. 2015;54(12):2249–56. https://doi.org/10.1093/rheumatology/kev257.

    PubMed  Google Scholar 

  61. Adler S, Körner M, Förger F, Huscher D, Caversaccio MD, Villiger PM. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study. Arthritis Care Res. 2013;65(11):1862–8. https://doi.org/10.1002/acr.22052.

    Article  CAS  Google Scholar 

  62. Meiners PM, Vissink A, Kroese FGM, Spijkervet FKL, Smitt-Kamminga NS, Abdulahad WH, et al. Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73(7):1393–6. https://doi.org/10.1136/annrheumdis-2013-204653.

    Article  CAS  PubMed  Google Scholar 

  63. Tsuboi H, Matsumoto I, Hagiwara S, Hirota T, Takahashi H, Ebe H, et al. Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s syndrome Endocrinopathy) trial. Mod Rheumatol. 2016;26(6):891–9. https://doi.org/10.3109/14397595.2016.1158773.

    Article  CAS  PubMed  Google Scholar 

  64. Harboe E, Tjensvoll AB, Vefring HK, Gøransson LG, Kvaløy JT, Omdal R. Fatigue in primary Sjögren’s syndrome—a link to sickness behaviour in animals? Brain Behav Immun. 2009;23(8):1104–8. https://doi.org/10.1016/j.bbi.2009.06.151.

    Article  CAS  PubMed  Google Scholar 

  65. Norheim KB, Harboe E, Gøransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjögren’s syndrome—a double blind, randomised clinical trial. PLos ONE. 7(1):e30123. https://doi.org/10.1371/journal.pone.0030123.

  66. Halse A, Tengner P, Wahren-Herlenius M, et al. Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjögren’s syndrome. Scand J Immunol. 1999;49(5):533–8. https://doi.org/10.1046/j.1365-3083.1999.00533.x.

    Article  CAS  PubMed  Google Scholar 

  67. Tishler M, Yaron I, Geyer O, et al. Elevated tear interleukin-6 levels in patients with Sjögren syndrome. Ophthalmology. 1998;105(12):2327–9.36

    Article  CAS  PubMed  Google Scholar 

  68. Tishler M, Yaron I, Shirazi I, Yossipov Y, Yaron M. Increased salivary interleukin-6 levels in patients with primary Sjögren’s syndrome. RheumatolInt. 1999;18(4):125–7. https://doi.org/10.1007/s002960050070.

    Article  CAS  Google Scholar 

  69. Justet A, Ottavianai S, Dieude P, et al. Tocilizumab for refractory organising pneumonia associated with Sjögren’s disease. BMJ Case Rep. 2015;2015(may14 1):bcr2014209076. https://doi.org/10.1136/bcr-2014-209076.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Komai T, Shoda H, Yamaguchi K, Sakurai K, Shibuya M, Kubo K, et al. Neuromyelitis optica spectrum disorder complicated with Sjögren syndrome successfully treated with tocilizumab: a case report. Mod Rheumatol. 2016;26(2):294–6. https://doi.org/10.3109/14397595.2013.861333.

    PubMed  Google Scholar 

  71. Nilolay N, Illei G. Pathogenesis of Sjögren’s syndrome. Curr Opin Rheumatol. 2009;21(5):465–4470.

    Article  Google Scholar 

  72. Voulgarelis M, Tzioufas A. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren’s syndrome. Nat Rev Rheumatol. 2010;6(9):529–37. https://doi.org/10.1038/nrrheum.2010.118.

    Article  CAS  PubMed  Google Scholar 

  73. Mariette M, Gottenberg J-E. Pathogenesis of Sjögren’s syndrome and therapeutic consequences. Curr Opin Rheumatol. 2010;22(5):471–7.

    Article  CAS  PubMed  Google Scholar 

  74. Maravragani C, Nezos A, Moutsopoulos H. New advances in the classification, pathogenesis and treatment of Sjögren’s syndrome. Curr Opin Rheumatol. 2013;25:623–9.

    Article  Google Scholar 

  75. Fox R Pathogenesis of Sjögren’s syndrome. UptoDate (P. Shur, P.Romain Eds.) https://www.uptodate.com/contents/pathogenesis-of-sjogrens-syndrome, Wolters Kluwer, January 2017.

  76. Faustman D, Alevizos I. Investigation of repeat BCG vaccinations in autoimmunity: rationale and phase I trial in Sjögren’s syndrome: S13.3. Scand J Immunol. 2015;81(5):428–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Conflict of Interest

Dr. Johr reports consulting honoraria from Kaiser Associates, L.E.K. Consulting, and KeyQuest Health, Inc. outside the submitted work and is a member of the Sjögren’s Syndrome Foundation Board of Directors.

Dr. Vivino reports personal fees and grant support from Biogen-Idec, Inc., personal fees, grant, and non-financial support from Immco Diagnostics, Inc., and personal fees from Novartis, Inc. outside the submitted work; also, former member of the Sjögren’s Syndrome Foundation Board of Directors, former Chair of SSF Medical & Scientific Advisory Board and, former Chair of the SSF Clinical Practice Guidelines Committee. Author of cited articles in this paper.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by either of the authors.

Additional information

This article is part of the Topical Collection on Other CTD: Inflammatory Myopathies and Sjögren’s

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Johr, C.R., Vivino, F.B. Biologic Therapy in the Treatment of Sjögren’s Syndrome: a Clinical Perspective. Curr Treat Options in Rheum 4, 85–98 (2018). https://doi.org/10.1007/s40674-018-0091-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40674-018-0091-5

Keywords

Navigation